Population Pharmacokinetic Analysis for a Single 1,200-Milligram Dose of Oritavancin Using Data from Two Pivotal Phase 3 Clinical Trials

Oritavancin is a lipoglycopeptide antibiotic with activity against Gram-positive bacteria. Here we describe oritavancin population pharmacokinetics and the impact of patient-specific covariates on drug exposure variability. Concentration-time data were analyzed from two phase 3 clinical trials, SOLO...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Antimicrob Agents Chemother
Asıl Yazarlar: Rubino, C. M., Bhavnani, S. M., Moeck, G., Bellibas, S. E., Ambrose, P. G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Microbiology 2015
Konular:
Pharmacology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4432154/
https://ncbi.nlm.nih.gov/pubmed/25824211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00176-15
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller